Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Igor Palacios

Interventional Cardiology Boston, MA Medical Doctor

NPI 1376533562 CMS profile 16319

55 Fruit St, Grb 800, Boston, MA 02114

Open in the dashboard

General payments

$7,467

39 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$152,741 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Igor Palacios of Boston, MA is reported in the CMS Open Payments database as having received $7,467 across 39 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $152,741 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 50th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $390 6
2024 General $329 10
2023 General $2,692 4
2022 General $376 4
2021 General $2,000 1
2019 General $1,681 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Igor Palacios
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Igor Palacios were reported at $390. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Igor Palacios Interventional Cardiology median Middle half National median
2019 $1,681 $1,097 $329–$3,048 $163
2020 $0 $473 $161–$1,480 $114
2021 $2,000 $677 $233–$1,827 $132
2022 $376 $978 $333–$2,724 $149
2023 $2,692 $1,136 $382–$2,986 $160
2024 $329 $1,181 $395–$3,326 $164
2025 $390 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $4,500 2 payments
  2. Boston Scientific Corporation $1,445 21 payments
  3. Abbott Laboratories $641 6 payments
  4. Medtronic Vascular, Inc. $287 2 payments
  5. Edwards Lifesciences Corporation $136 1 payment
  6. Cook Medical LLC $134 2 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $98 1 payment
  8. Medtronic, Inc. $88 2 payments
  9. AstraZeneca Pharmaceuticals LP $79 1 payment
  10. W. L. Gore & Associates, Inc. $58 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Honoraria $2,500 1 payment
  2. Food and Beverage $2,376 32 payments
  3. Consulting Fee $2,000 1 payment
  4. Travel and Lodging $592 5 payments
Products named General payments · program years 2019–2025
  1. General Therapies $661 6 payments
  2. Sentinel $202 4 payments
  3. MITRACLIP $168 2 payments
  4. AMPLATZER Occluders $167 1 payment
  5. GENERAL ATHERECTOMY $150 1 payment
  6. Mitra Clip system $149 1 payment
  7. GENERAL STRUCTURAL HEART $147 1 payment
  8. COOK $134 2 payments
  9. DRAGONFLY OPSTAR $114 1 payment
  10. General - Vascular Access $109 1 payment
  11. Other $527 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

386

Median for Interventional Cardiology: 2,236

Drug cost

$38,105

Median for Interventional Cardiology: $380,412

Branded share of claims

13.7%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 21 $32,977
Metoprolol Succinate Generic 96 $1,705
Valsartan Generic 14 $638
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 21 $453
Atorvastatin Calcium Generic 42 $393
Losartan Potassium Generic 29 $384
Furosemide Generic 37 $343
Ezetimibe Generic 11 $314
Omeprazole Generic 16 $291
Amlodipine Besylate Generic 42 $222

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$20,161

Medicare's payments for the services billed

Medicare patients

96

Average age 78

Services billed

219

38 women, 58 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 52%
Atrial fibrillation 42%
Heart failure 39%
Diabetes 35%
Chronic kidney disease 30%
Osteoporosis 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

39 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record